Last update 11 Jul 2024

Senaparib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationSpecial Review Project (CN), Orphan Drug (US)

Structure

Molecular FormulaC24H20F2N6O3
InChIKeyVBTUJTGLLREMNW-UHFFFAOYSA-N
CAS Registry1401682-78-7

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaNDA/BLA
CN
28 Aug 2023
Fallopian Tube CarcinomaNDA/BLA
CN
28 Aug 2023
Ovarian CancerNDA/BLA
CN
28 Aug 2023
Ovarian CancerNDA/BLA
CN
28 Aug 2023
Ovarian Epithelial CarcinomaNDA/BLA
CN
28 Aug 2023
Ovarian Epithelial CarcinomaNDA/BLA
CN
28 Aug 2023
Primary peritoneal carcinomaNDA/BLA
CN
28 Aug 2023
Primary peritoneal carcinomaNDA/BLA
CN
28 Aug 2023
Small Cell Lung CancerPhase 2
AU
28 Sep 2021
BRCA-mutated Ovarian CancerPhase 1
CN
11 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Ovarian Cancer
BRCA1 Mutation | BRCA2 Mutation
93
(xhghdhuohe) = haznqzpohv xbormbklpg (smztcdpohh, 86.2 - 97.5)
Positive
22 Oct 2023
Phase 3
Ovarian Cancer
Maintenance
404
(qpdtpdpaju) = mqudwtrpib vftgtqjcjz (gsqmehiblp )
Positive
20 Oct 2023
Placebo
(qpdtpdpaju) = lycnxsxgdi vftgtqjcjz (gsqmehiblp )
Phase 3
Ovarian Cancer
Maintenance
high-grade serous | endometrioid tumors
404
(gulvcpowho) = jlbpoqxugl kaxzwauobe (ovsethdkqt )
Positive
28 Sep 2023
Placebo
(gulvcpowho) = vzmnlffved kaxzwauobe (ovsethdkqt )
Phase 1/2
42
(gqrxmdrlfo) = wwltfqotrb pbcdhksmin (iwwyorfkhg, 5.4 - 28.5)
Positive
12 Sep 2023
(Platinum sensitive)
(gqrxmdrlfo) = epvquxrovd pbcdhksmin (iwwyorfkhg, 2.4 - 30.2)
Phase 1
57
(ahnocwpgrn) = qzmdiqryje tgqltrwagy (elsjwffpnj )
-
20 Jun 2023
Phase 1
39
(tyafijeduj) = Most treatment-emergent adverse events were grade 1-2 (91%). Seven patients (17.9%) reported hematologic treatment-emergent adverse events. Treatment-related adverse events occurred in eight patients (20.5%), and the most frequent was nausea (7.7%). Two deaths were reported after the end of study treatment, one of which was considered a complication from senaparib-related bone marrow failure. cwwozwrdts (fjvebqnpxd )
-
31 Jan 2023
Phase 1
14
(mnmzsnvsnk) = The MTD and RP2D were determined as: senaparib 80 mg plus temozolomide 20 mg. cvdybmevml (xhkhrdtrlg )
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free